<4D F736F F F696E74202D20BEE0C0CEBCBA20B0A3BCD5BBF328C8E6B9E9292DC1A4BCF7C7E22E BC8A3C8AF20B8F0B5E55D>

Similar documents
<B0E6C8F1B4EBB3BBB0FAC0D3BBF3B0ADC1C E687770>

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

γ

<30382EC0C7C7D0B0ADC1C22E687770>

Clinical Symposium 1 The use of drug in patient with chronic liver disease Sung Bum Cho Department of Internal Medicine, Chonnam National University M


08-ÀåÀμö

untitled

간질환 환자에서의 수술 위험도 평가 및 흔히 접하는 타과 협진 의뢰

00약제부봄호c03逞풚

歯간학회지6-2.PDF

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

농림수산식품부장관귀하 이보고서를 팥의대사성질환개선및기능성규명 에관한연구의최종보고서로제출 합니다 년 2 월 11 일 - 1 -

<313020BFF8C0FA C0D3C0E7C8F12E687770>

fm

( )Kju269.hwp

Overview -ingredient - mechanism 2. Biomarker 3. In vitro study 4. In vivo study 5. Human study 6. 기능성 인정서 7.기준규격 인정서

歯채민병.PDF

ÀÇÇа�ÁÂc00Ì»óÀÏ˘

Treatment and Role of Hormaonal Replaement Therapy

한약치료와표적항암요법 ( 아피니토 ) 을병행하여부분관해된신세포암간전이환자 1 례 Abstract Sung-Hwan Chang 1, Ji-Hye Park 1,2, Hwa Seung Yoo,2*

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

서강대학교 기초과학연구소대학중점연구소 심포지엄기초과학연구소

<B0E6C8F1B4EBB3BBB0FAC0D3BBF3B0ADC1C E687770>

김범수

06(14-17)p fm

Microsoft PowerPoint Free Papers (Abstracts)12.ppt


한국성인에서초기황반변성질환과 연관된위험요인연구

대한임상독성학회지 2012:10(2):97~102 Volume 10, Number 2, December, 2012 Journal of The Korean Society of Clinical Toxicology 원 저 Acetaminophen 중독환자에서 N-Acetyl

간행사 대한결핵 및 호흡기 학회 회원 여러분 안녕하십니까? 저희 학회가 금년 봄 100회째의 학술대회를 성공적으로 마침에 때 맞추어 우리나라 호흡기 질환 중에서도 비교 적 흔한 폐결핵, 폐렴, 천식과 COPD의 진료지침서를 발간하게 됨을 매우 뜻 깊게 생각합니다. 이러



15(1)-04(국)(p.27-33).fm

PowerPoint 프레젠테이션

388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

약품정보 1110.hwp

<313320C1F5B7CA C0FCBCBAC1F82DB1E8C5C2BFEB D E687770>

2012 년대한간학회추계학술대회 임신과관련된생리학적간기능변화 임신에의해일어나는생리학적변화는혈액량및혈장량증가, 심장박출량및심박수증가, 전신혈관저항감소등으로요약할수있으며간의합성능이나간으로의혈류등은변화가없으나콜레스테롤분비의증가, 담낭의운동성저하등에의해담낭의크기가증가하고담석이

2. Cyclosporine, Tacrolimus Cyclosporine과자몽주스와의상호작용에대해서는특별한주의가요구된다. 칼슘길항제와는달리 AUC 및 Cmax 상승률이 10~50% 에불과하지만 cyclosporine은치료역 (therapeutic range) 이좁기때문

<5B31362E30332E31315D20C5EBC7D5B0C7B0ADC1F5C1F8BBE7BEF720BEC8B3BB2DB1DDBFAC2E687770>

°Ç°�°úÁúº´5-44È£ÃÖÁ¾

α α α α α

Liver Site-Specific Factor1 - Alpha Fetoprotein(AFP) Interpretation (Liver, Intrahepatic Bile Ducts) Site-Specific Factor3 - Alpha Fetoprotein(AFP) La

056~

Kjcg007( ).hwp


<B0A3C3DFB0E820BABBB9AEBFDC2E687770>

12-17 총설.qxp

<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>

È£(ÃÖÁ¾).ps, page Normalize

PowerPoint 프레젠테이션

한약재품질표준화연구사업단 작약 ( 芍藥 ) Paeoniae Radix 생약연구과

< B3E220C1F6BFAABBE7C8B820C5EBC7D5B0C7C1F5C1F8BBE7BEF720BEC8B3BB28C3D6C1BEC0CEBCE2292E687770>

신약개발과정에서의약물대사연구 한국생명공학연구원오수진선임연구원 1. 서론 신약개발은많은시간과노력그리고높은비용을소모하는과정이지만높은부가가치를창출할수있는산업이다. 신약개발을위한임상연구과정에서의주요실패요인이약물대사및약물동태 (pharmacokinetics, PK) 로알려진 1




노영남

<30332E B4EBC7D1B0A1C1A4C0C7C7D0C8B820BCADBFEFC1F6C8B820C3E1B0E82DC3D6C1BE2E687770>

<30322E535453BABBB9AE2DC6EDC1FD2E687770>

( )Jkstro011.hwp


< C0D3BBF3B0C7B0AD20C3E1B0E8C7D0BCFAB4EBC8B82DBFACBCF6B0ADC1C22E687770>

박치영논문-1

<C3D6C1BE5F2D FBCF6C1A42E687770>

< DB0C7C3E0C1F6B8EDBFF82D28C4ABB4DEB7CEB1D72BC1F6B8EDBFF829202D E706466>

<30352EB0A3BAB4B8AE2E687770>


Jksvs019(8-15).hwp

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

°Ç°�°úÁúº´6-2È£

저작자표시 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 이차적저작물을작성할수있습니다. 이저작물을영리목적으로이용할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니

전체 목차 1. 주류 일반 2. 기능성 3. 숙취 4. 주세법 5. 주류 일반 상식 6. 우리술 즐기기

untitled

(48-67).hwp

ePapyrus PDF Document

PJTROHMPCJPS.hwp

ÀÇ»çȸº¸ È£-14, page Normalize ( È£-14 )

,,,,,,,, (), BOD,,,,,,,,,

ca

Microsoft PowerPoint - Labs and Lupus Bev2 24

<B0EDC1F6C7F7C1F5BEE0B9B0BFE4B9FD FC0FAC0DAB0CBC5E4BFCFB7E12E687770>

Kaes025.hwp

untitled

YBM시사닷컴, 첨단 개인별 맞춤 학습 시스템 개발

<C3D6C1BEBAB8B0EDBCAD28BCD5BBF3B8F1292E687770>

Risk of Developing Hypertension by Daily Intake of Alcohol

<C7D1BDC4BFAC20B1E8B5BFBCF6B9DABBE7B4D4676C75636F20C3D6C1BE5B315D2E687770>


<322E20BEC6BDC3BEC62D32C2F728BCF6C1A4292E687770>

<B0A3C3DFB0E828C0DBBEF7292E687770>

슬라이드 1

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345])

<4D F736F F F696E74202D204E494345BCADC8ABBFF8B0ADC0C7B7CF31205BC8A3C8AF20B8F0B5E55D>

편집순서 3 : 목차 - 2 -

보건사회연구-25일수정

1..

6.Kaes013( ).hwp

Transcription:

약인성간손상 2005.8.28 개원의연수강좌 분당서울대학교병원내과정숙향

약인성간손상의중요성 2002년, 등록된 chemical 수 > 360만개, 매일 400개이상등록추가 미국 FDA approved drugs > 1만개 대체보완요법의사용빈도증가 약인성간손상증례는앞으로지속적으로증가할것임 입원환자의황달원인중 2% 는약제에의함 급성간부전례의 20% 정도가약제에의함 약인성간손상은거의모든종류의간질환으로나타날수있음

급성간부전에서약인성간손상의중요성 AAP/ Other Drugs HAV/ HBV Shock/ Others Indeter Argentina, 96-01, n=83 0 / 14% 8 / 22% 0 / 31% 25% Denmark, 73-90, n=160 19 / 17% 2 / 31% 3 / 13% 15% France, 72-90, n=502 2 / 17% 4 / 32%? / 27% 18% India, 87-93, n=423 0 / 5% 2 / 31% 0 / 62% 0 Japan, 92-99, n=38 0 / 0 3 / 18% 0 / 8% 71% UK, 93-94, n=342 73 / 2% 2 / 2% 3 / 9% 8% USA, 94-96, n=295 20 / 12% 7 / 10% 3 / 33% 15% USA, 98-01, n=308 39 / 13% 4 / 7% 6 / 15% 17%

약의간내대사과정 Uptake: sinusoidal mb. TP Metabolism Canalicular mb. TP Phase I (CYPs) :SER toxification Phase II (conjugation) : cytosol detoxification Phase III (efflux)

약인성간손상의병인론 (1) Drug metabolite Covalent binding Oxidative stress Metabolite Haptenization Mitochondria Bioenergetic Catastrophe: ATP Organellar stress, Altered signal transduction/ gene exp. Mitochondria Adaptive / Innate immune response sensitization Necrosis Apoptosis

약인성간손상의병인론 (2) 내인성간독성 용량-의존적 예측가능 재현가능 간소엽의특정부위침범 짧은잠복기 ( 수시간-수일 ) 예 : acetaminophen 특이반응성간독성 용량 - 비의존적 예측불가능 치료용량에서도가능 긴잠복기 ( 수주 - 수개월 ) 면역학적특이반응 대사성특이반응 ( 대사효소장애, 유전적다형성 ) 예 : phenytoin, INH

약인성간독성의병인론 (3) 약제에의한요인 toxic potential, reactive metabolite, mitochondria effects 숙주에의한요인 Age Gender Race Renal ds, Liver ds, Obesity, HIV/AIDS Alcohol Genetic polymorphism or defects: P450 2D6(perhexiline maleate), Urea cycle(valproate), mitochondrial beta-oxidation(valproate, ASA), UDP glucuronosyl transferase(aap)

약인성간손상의임상양상 by CIOMS (Council for International Organization of Medical Sciences) 간손상 : ALT, 총빌리루빈, ALP 중하나이상이정상상한치의 2 배이상인경우 급성 / 만성약인성간손상 : 3(-6) 개월기준 심한간손상 : 황달, PT 연장 (INR>1.5), 간성혼수 ALT Hepatitis Cholestasis ALP (Alkaline P-tase) Mixed >2N in ALT alone or ALT/ALP ratio 5 >2N in ALP alone or ALT/ALP ratio 2

약인성간손상의병리양상 Acute Hepatitis acetaminophen Isoniazid, halothane ketoconazole troglitazone Acute Cholestasis augmentin/ EM sulindac/piroxicam estrogen allopurinol NASH MTX amiodaron tamoxifen valproate Chronic Hepatitis methyl dopa MTX nitrofurantoin minocycline Chronic Cholestasis (ductopenic) Same Others VOD (ChemoTx) Tumors (estrogen, aflatoxin, vinyl chloride)

약인성간독성의진단 (1) 간기능이상환자에서복용한약에관한병력을자세히얻을것 정확한진단보다는의심되는약물을빨리찾아내어늦기전에약을중단하는것이중요함

약인성간독성의진단 (2) 임상적특징과잠복기 : 복용후 5-90 일이내발생 약을중단했을때호전여부 : 중단후 8 일이내 ALT 50%, Bilirubin 50% 감소 다른원인에의한간손상을배제 : 바이러스성간염, 자가면역성간염, 담도페쇄성질환, 대사성질환등 ( 의도치않은 ) 재투여시악화 상황증거에근거한진단이라정확성이떨어짐 Scoring system RUCAM scoring system, Maria/ Victorino system

RUCAM Scoring System: CIOMS scale (Council for International Organizations of Medical Sciences) Rousel UCLAF Causality Assessment Method latency : 투여시작후 5-90day/ 투여종료후 15day rate of resolution on withdrawal : ALT/ALP 50% reduction for 8d/1mo. risk factors: alcohol, old age concomitant drugs exclusion of competing causes : viral hepatitis, bile duct obstruction, alc. etc tract record of the drug response to rechallenge Probability of association between drug and liver injury: Score range: -5 ~ +14 Exclude -5-0, Unlikely 1-2, Possible 3-5 Probable 6-8, Highly probable >8

독성간손상 : 우리나라다기관연구 2003-3-10, 7 개대학병원, 입원한독성간염환자 76 명 나이 : 54 ± 28 (23-81 세 ), 남녀비 : 26/50 원인 : 한약 (44.7%), 한약재 (13.2%) 민간요법, 건강식품 (25.0%) 약국매약 (1.3%), 의사처방 (14.5%), 불명 (1.3%) 복용기간 : 43 ±82 (2-163 일 ) 검사소견 : AST 907 (98-6320), ALT 996 (34-6060), ALT 304 (71-1845), TB 8.8 (0.5-41) RUCAM score: 7.5 ±3.2 (4-11) 사망례 : 2/72 : CH-B+herb, Anti-Tbc med+herb

Acetaminophen (AAP) (1) AAP Conjugation : sulfate glocuronate CYP450: 2E1, 1A2, 3A4 NAPQI: Toxic metabolite Conjugation with GSH ->Cysteine derivatives Covalent binding to cell proteins Oxidative stress Renal excretion Cell death Disruption of cell Ca++ homeostasis NAPQI:N-acetyl- p-benzoquinone imine GSH: glutathione

Acetaminophen (AAP)(2) 어른에서는 7.5g 이상복용시간독성유발, 20g 이상복용시사망 2-6g 을수개월 - 수년복용시에만성간독성예도있음 병리적으로는 zone 3 necrosis, 염증반응은거의없음 간독성을악화시키는요인 금식, 음주, 동시복용약제 (isoniazid, phenytoin, phenobarbital, carbamazepine, zidovudine, etc.) FDA guideline: not use after consuming > 3 drinks (alcohol 36g) daily 어린이, 일찍발견되어해독제사용한예에서예후가좋음 복용후 12-24 시간이내 N-acetylcystein 을주면예후가좋음

Acetaminophen (AAP)(3) 임상양상 복용후 24 시간 : nausea, vomiting, diaphoresis 복용후 2-4 일 : 무증상 (latency period) 복용후 3-10 일 : 간부전, 신부전 회복기혹은사망 Serum AAP level correlates with liver damage 치료 위장세척 ( 복용후 1-3 시간 ) N-acetylcysteine PO/ IV within 16hr of ingestion Stimulate hepatic production of reduced glutathione PO: 140mg/kg 70mg/kg q 4hr x 17 doses Rash, diarrhea, anaphylactoid reaction Methionine (2.5g loading 2.5g q 4hr x 4), cimetidine

NASID/ COX-2 inhibitor/ Anti-rheumatoid Aspirin: >2-6g/day, pt s having connective ts.ds.( 고위험군 ) * Reye s synd.: microvesicular hepatic steatosis, acute encephalopathy, inborn error of mitochondrial enzymes 대부분 NASIDs: idiosyncratic, hepatocellular injury, 복용중단하면예후는양호함 Celecoxib: 다른 NASID보다간독성빈도가낮은편 Allopurinol: systemic side effect에비해간독성은드문편, 복용후 1-5주후에발진, 발열, 호산구증다증등을동반, 병리적으로 granuloma 형성 Methotrexate: stellate cell activation, hepatic fibrosis, 간조직검사상중등도이상의간섬유화가있을시는반드시중단

Anti-microbials/Anti-Tbc drugs Amoxicillin-clavulinic acid (cholestasis), oxcillin Cephalosporin: extremely rare Erythromycin, Quinolones: cholestasis Tetracyclin, minocyclin: microvesicular steatosis, AIH-like Ketoconazole, fluconazole, terbinafine: hepatocellular injury Isoniazid: 첫 3개월에 10-20% 의환자에서 ALT상승, 약을계속써도대부분정상화됨, 고령, 과음주자, HBV, HIV 감염자에서위험 Rifampin: potent CYP450 inducer, inhibitor of bilirubin uptake, isoniazid 간독성을증가시킴 Pyrazineamide: 항결핵제중에서가장간독성이큼. INF+RFP+PZA 함께쓰면간독성악화

Hypolipidemic/ Anticoagulants HMG-CoA Reductase (Statin) Dose-related, LFT abnormality in 5% for simvastatin, pravastatin No reports with cerivastatin, fluvastatin LFT monitoring: cost-effective? Fibrates Cholestasis, hepatitis, granulomatous change Mitochondrial damage, lithogenic (cholesterol gallstones) Niacin/ Nicotinic acid Dose-related, sustained- release form 에서심한경향 Heparin/ Coumarin derivatives

Anti-Hypertensive/-arrythmic Drugs ACEI / ARA: cholestatic injury Beta-Blocker: rare, labetalol (hepatocellular) Calcium-channel blocker: rare Diuretics: very rare Methyl-dopa safe in pregnancy, acute hepatocellular injury-chronic hepatitis resembling autoimmune hepatitis with autoimmune phenomena Hydralazine Safe in pregnancy, hepatocellular type * Amiodarone Phospholipidosis, pseudoalcoholic liver ds. with steatosis

Estrogens cholestasis cholesterol gallstone formation Hormones hepatic tumors (adenoma, FNH, carcinoma?, hemangioendothelioma) Budd-Chiari synd. Tamoxifen: NASH, cholestasis Androgens: cholestasis, peliosis, hepatic tumors Glucocorticoids : steatosis/ NASH Anti-thyroid drugs PTU: LFT abnormality in 25% with fever, rash, arthralgia Methimazole: cholestasis

Oral hypoglycemic agents Sulfonylurea: 투여 1 개월내발생, rare, cholestatic type Biguanide: rare, cause lactic acidosis/ low hepatotoxicity α-glucosidase inhibitor: ALT >3N in 3% Thiazolidinediones: PPAR-γ agonists Troglitazone: fatal hepatotoxicity, withdrawn from market Rosiglitazone: case of ALF+ Pioglitazone: less hepatotoxicity Monitor LFT q 2Mo for the 1st 12Mo. Discontinue if ALT>3N Effect of monthly monitoring: questionable

그외상용약제 위산분비억제제 H2 blocker: cholestasis, hepatitis, CMT > Ranitidine, Famotidine PPI: rare 항히스타민제 Cetrizine, terfenadine, chlorpheniramine

한약, 민간요법등에의한간손상 Pyrrolizidine alkaloids: VOD (Venoocclusive disease) Senecio, symphytum(comfrey), Crotalaria, Heliotropium 체중감량용약제 Germander(Teucrium), lipokinetix, 중국산체중감량식품 중국산한약재 기타 작약, 용담, 시호, 백선, 마황, 진부환, 황련, 등 Greater celandine( 애기똥풀추출물 ) Pennyroyal oil( 박하 ) Ackee fruit, artichoke( 채소뿌리일종 ), kava, cycasin( 소철류열매성분 ), senna( 변비치료제 ), mistletoe( 겨우사리 ), Chaparral( 떡갈나무일종 )

건강기능식품과타약제간의약물상호반응의예 St. John s wort (Hypericum perforatum) Used as antidepressant Hyperporin binds to nuclear receptor (PXR) CYP3A4, MDR1 expression interaction with cyclosporin; lower blood conc. in liver transplantation recipient organ rejection risk Grapefruit juice, lime juice Bergamottin ingredient: Suppression of CYP3A4 digoxin toxicity

간손상이없는한약재 Aloe: wound healing Chamomile: insomnia, antiseptic Cranberry: urinary tract infection Dandelion root: diuretic Feverfew: arthritis, migraines Garlic: cholesterol-lowering, anti-hypertensive Ginger: concentration, increase stamina Gingko biloba: memory improvement, claudication Ginseng: stimulant Peppermint: analgesic Glucosamine; arthritis

내용정리 날로증가하는약제사용과함께약의주대사기관인간손상도증가하고있다. 처방약제의간손상가능성을염두에두고, 간손상을조기진단하여원인약제를조기중단하는것이중요하다. 여러약물간의상호작용, 대체요법제의사용도의사가관리해야할부분이다.

약물정보탐색에유용한사이트 http://www.micromedex.com http://www.kimsonline.co.kr http://medlineplus.gov http://www.fda.gov/cder http://www.fda.gov/medwatch http://toxnet.nlm.nih.gov/